Document is current
Any future updates will be listed below
-
Authors
Ford, Brittany L. https://orcid.org/0000-0003-2301-7799
Jokinen, Emmi
Huuhtanen, Jani https://orcid.org/0000-0003-2750-4033
Forstén, Sofia https://orcid.org/0009-0002-4835-3334
Klievink, Jay
Antignani, Gabriella https://orcid.org/0000-0001-9388-8632
Brück, Oscar https://orcid.org/0000-0002-7842-9419
Cerullo, Vincenzo
,
Peltonen, Karita https://orcid.org/0000-0002-3063-451X
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
-
Funding
Funding for this research was provided by:
Academy of Finland
Signe ja Ane Gyllenbergin Säätiö
Jane ja Aatos Erkon Säätiö
Syöpäsäätiö
Helsinki Institute of Life Sciences
Suomen Kulttuurirahasto (00220227, 00240108)
- License Information
-
More Information
Article History
Received: 14 March 2025
Revised: 16 July 2025
Accepted: 1 August 2025
First Online: 22 August 2025
Competing interests
: SM has received honoraria and research funding from BMS and Novartis, research funding from Pfizer, and honoraria from Dren-Bio (unrelated to the submitted work). VC is a co-founder and shareholder of Valo Therapeutics LTD (unrelated). OB declares consultancy fees from Novartis, Sanofi, Roche, GSK, and Amgen; research grants from Pfizer and Gilead Sciences; stock ownership of Hematoscope Ltd (unrelated). JH declares consultancy fees from Daiichi-Sankyo (unrelated). The other authors declare that they have no competing interests.
